Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v3.5.0.2
Segments (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue $ 4,231,719 $ 1,963,548 $ 8,014,399 $ 3,798,970 $ 10,300,000
Lymphoseek license revenue 245,950 250,000 500,000 333,333  
Grant and other revenue 916,811 654,360 1,602,636 844,061  
Total revenue 5,394,480 2,867,908 10,117,035 4,976,364  
Cost of goods sold, excluding depreciation and amortization 546,466 304,495 1,041,105 725,046  
Research and development expenses, excluding depreciation and amortization 2,525,581 2,292,524 5,185,101 6,269,262  
Selling, general and administrative expenses, excluding depreciation and amortization 2,784,637 3,932,267 6,771,995 9,309,669  
Depreciation and amortization 117,778 149,317 267,370 299,139  
Income (loss) from operations (579,982) (3,810,695) (3,148,536) (11,626,752)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (6,098,405) (5,874,019) (7,203,861) (5,086,960)  
Equity in the loss of R-NAV, LLC (2,920) (6,205) (15,159) (268,432)  
Net income (loss) (6,681,307) (9,690,919) (10,367,556) (16,982,144)  
Total assets, net of depreciation and amortization 8,682,149   8,682,149   $ 14,964,513
Payments to Acquire Property, Plant, and Equipment 1,847 27,618 1,847 27,618  
United States [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 4,218,606 1,962,898 7,990,026 3,793,920  
Total assets, net of depreciation and amortization 8,360,199 21,726,705 8,360,199 21,726,705  
International [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 13,113 650 24,373 5,050  
Total assets, net of depreciation and amortization 321,950 471,884 321,950 471,884  
Corporate [Member]          
Segment Reporting Information [Line Items]          
Selling, general and administrative expenses, excluding depreciation and amortization 1,644,649 2,339,207 4,620,499 5,660,068  
Depreciation and amortization 103,504 116,532 212,806 233,298  
Income (loss) from operations (1,748,153) (2,455,739) (4,833,305) (5,893,366)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (6,098,405) (5,874,019) (7,203,861) (5,086,960)  
Equity in the loss of R-NAV, LLC (2,920) (6,205) (15,159) (268,432)  
Net income (loss) (7,849,478) (8,335,963) (12,052,325) (11,248,758)  
Payments to Acquire Property, Plant, and Equipment 1,847 2,126 1,847 2,126  
Corporate [Member] | United States [Member]          
Segment Reporting Information [Line Items]          
Total assets, net of depreciation and amortization 3,701,620 17,690,779 3,701,620 17,690,779  
Corporate [Member] | International [Member]          
Segment Reporting Information [Line Items]          
Total assets, net of depreciation and amortization 591 1,851 591 1,851  
Diagnostics [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek license revenue 245,950 250,000 500,000 333,333  
Grant and other revenue 865,359 654,360 1,551,184 844,061  
Total revenue 5,343,028 2,867,908 10,065,583 4,976,364  
Cost of goods sold, excluding depreciation and amortization 546,466 304,495 1,041,105 725,046  
Research and development expenses, excluding depreciation and amortization 2,414,255 2,115,786 4,831,975 6,006,510  
Selling, general and administrative expenses, excluding depreciation and amortization 1,135,558 1,529,042 2,147,664 3,571,217  
Depreciation and amortization 14,274 32,785 54,564 65,841  
Income (loss) from operations 1,232,475 (1,114,200) 1,990,275 (5,392,250)  
Net income (loss) 1,232,475 (1,114,200) 1,990,275 (5,392,250)  
Payments to Acquire Property, Plant, and Equipment   25,492   25,492  
Diagnostics [Member] | Operating Segments [Member] | United States [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 4,218,606 1,962,898 7,990,026 3,793,920  
Total assets, net of depreciation and amortization 4,621,738 4,035,926 4,621,738 4,035,926  
Diagnostics [Member] | Operating Segments [Member] | International [Member]          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 13,113 650 24,373 5,050  
Total assets, net of depreciation and amortization 321,359 470,033 321,359 470,033  
Therapeutics [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Grant and other revenue 51,452   51,452    
Total revenue 51,452   51,452    
Research and development expenses, excluding depreciation and amortization 111,326 176,738 353,126 262,752  
Selling, general and administrative expenses, excluding depreciation and amortization 4,430 64,018 3,832 78,384  
Income (loss) from operations (64,304) (240,756) (305,506) (341,136)  
Net income (loss) (64,304) $ (240,756) (305,506) $ (341,136)  
Therapeutics [Member] | Operating Segments [Member] | United States [Member]          
Segment Reporting Information [Line Items]          
Total assets, net of depreciation and amortization $ 36,841   $ 36,841